ESR1 and breast carcinoma: These findings support a potential and profound conflict that depends on the which ER isomer has the predominant expression in HCC tissue, ERα-66 or ERα-36, and may explain why tamoxifen fails to inhibit tumors by antagonizing the estrogen signaling pathway as in breast cancer.